The global hemophilia treatment drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor that is expected to accelerate the growth of the market during the forecast period includes the rising burden of rare disorders among people globally. Hemophilia is a rare health condition in which an individual’s blood is not able to clot normally due to a lack of adequate blood-clotting factors. Manufacturers operating in the market are consistently focused on the development of novel and more efficient drugs. Hemophilia is caused by gene mutation, and around 70% of hemophilia cases are inherited. Moreover, the increasing awareness of such rare diseases among the population and government participation in the prevention and control of these life-threatening diseases are further driving the market growth.
To Request a Sample of our Report on Global Hemophilia Treatment Drugs Market: https://www.omrglobal.com/request-sample/hemophilia-treatment-drugs-market
In order to maintain a strong position in the market, the market players are adopting various strategic moves, such as product launches, partnerships and collaborations, and mergers and acquisitions. For instance, in July 2021, BioMarin Pharmaceutical Inc. announced the European Medicines Agency (EMA) approval for marketing authorisation of its investigational gene therapy valoctocogene roxaparvovec, for adults who are dealing with severe Hemophilia A. In May 2021, CSL Behring announced the completion of commercialisation and licensing agreement with uniQure for etranacogene dezaparvovec (AMT-061) for the treatment of Hemophilia B. The drug candidate is developed by uniQure and is currently in the Phase III clinical study.
Market Coverage
· The market number available for – 2020-2027
· Base year- 2020
· Forecast period- 2021-2027
· Segment Covered
· Regions Covered- Globally
· Competitive Landscape: Pfizer Inc., Novo Nordisk A/S, and Bayer AG, among others.
(Get 15% Discount on Buying this Report)
A full Report of Global Hemophilia Treatment Drugs Market is Available at: https://www.omrglobal.com/industry-reports/hemophilia-treatment-drugs-market
Global Hemophilia Treatment Drugs Market Report by Segment
By Drug Class
• Desmopressin
• Antifibrinolytic Agents
• Recombinant Coagulation Factor Concentrates
• Plasma Derived Coagulation Factor Concentrates
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Global Hemophilia Treatment Drugs Market by Region
North America
· United States
· Canada
Europe
· UK
· Germany
· Spain
· France
· Italy
· Rest of Europe
Asia-Pacific
· India
· China
· Japan
· South Korea
· Rest of APAC
Rest of the World
· Latin America
· Middle East & Africa
Reasons to buy from us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
